PARIS (Agefi-Dow Jones)–The pharmaceutical laboratory Sanofi announced Tuesday that the National Medicines Safety Agency (ANSM) in France had authorized the marketing (AMM) of Efluelda, its high-dose vaccine against influenza, in its trivalent version, which protects against three strains causing the same disease.
Sanofi has indicated that it is now continuing to work with the competent authorities to enable Efluelda to be available in France from the 2025-2026 influenza vaccination campaign, the French group indicated in a press release.
“This new marketing authorization for Efluelda aims to respond to the recommendation of the World Health Organization (WHO) to return to trivalent influenza vaccines. Indeed, the B/Yamagata strain is no longer circulating in the world, the maintenance of quadrivalent vaccines is no longer necessary,” Sanofi clarified.
Developed with a quantity of antigens four times greater than that of a standard dose vaccine for each vaccine strain, Efluelda is the only influenza vaccine having proven better effectiveness compared to the standard vaccine in people aged more than 60 years, added the laboratory.
-Pierre-Jean Lepagnot, Agefi-Dow Jones; +33 (0)1 41 27 48 19; [email protected] ed: LBO
Agefi-Dow Jones The financial newswire
(END) Dow Jones Newswires
November 05, 2024 05:02 ET (10:02 GMT)
Health
